Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Ibrutinib inhibits pre-BCR + B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK

Ekaterina Kim, Christian Hurtz, Stefan Koehrer, Zhiqiang Wang, Sriram Balasubramanian, Betty Y. Chang, Markus Müschen, R. Eric Davis, Jan A. Burger

Blood (2017) 129 (9): 1155–1165.

https://doi.org/10.1182/blood-2016-06-722900

Published: 2017

Includes: Supplemental data

Journal Articles

Ibrutinib Potentiated NK Cell-Mediated Cytotoxicity in Mouse Models of B-Cell Lymphomas

Hsu-Ping Kuo, PhD, Sidney Hsieh, MSc, Jennifer Whang, PhD, Yujun Huang, PhD, Mint Sirisawad, BS, Betty Y. Chang, PhD

Blood (2016) 128 (22): 4140.

https://doi.org/10.1182/blood.V128.22.4140.4140

Published: 2016

Journal Articles

Mutation Impact of Targeted Genes in Diffuse Large B-Cell Lymphoma Patients Treated with Ibrutinib

Leo WK Cheung, Karl J. Schweighofer, Shiquan Wu, Hsu-Ping Kuo, Karl Eckert, Sriram Balasubramanian, PhD, Deborah Ricci, Yu Liang, Darrin Beaupre, Betty Y. Chang

Blood (2015) 126 (23): 2642.

https://doi.org/10.1182/blood.V126.23.2642.2642

Published: 2015

Journal Articles

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

Patrick P. Ng, Daniel K. Lu, Juthamas Sukbuntherng, Jutta K. Neuenburg, Danelle F. James, Betty Y. Chang, PhD

Blood (2015) 126 (23): 3998.

https://doi.org/10.1182/blood.V126.23.3998.3998

Published: 2015

Journal Articles

The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma

Hsu-Ping Kuo, Sidney Hsieh, Karl J. Schweighofer, Leo WK Cheung, Shiquan Wu, Mutiah Apatira, Mint Sirisawad, Karl Eckert, Yu Liang, Jeff Hsu, Betty Y. Chang, PhD

Blood (2015) 126 (23): 699.

https://doi.org/10.1182/blood.V126.23.699.699

Published: 2015

Journal Articles

Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study

Blood (2015) 126 (23): 833.

https://doi.org/10.1182/blood.V126.23.833.833

Published: 2015

Journal Articles

In Vivo Evidence That Ibrutininb Deregulates Chemokine Receptor CXCR4 Surface Membrane Expression and Signaling, Along with Inhibiting B Cell Antigen Receptor Signaling, As Causes for Defective Homing and Impaired Retention of CLL Cells in Tissues

Shih-Shih Chen, PhD, Betty Y. Chang, Stella Chang, Timothy Tong, Yong-Rui Zou, Barbara Sherry, PhD, Joseph J. Buggy, PhD, Jan A. Burger, MD PhD, Kanti R. Rai, MD, Nicholas Chiorazzi, MD

Blood (2014) 124 (21): 1948.

https://doi.org/10.1182/blood.V124.21.1948.1948

Published: 2014

Journal Articles

Combination of Ibrutinib and BCL-2 or SYK Inhibitors in Ibrutinib Resistant ABC-Subtype of Diffuse Large B-Cell Lymphoma

Hsu-Ping Kuo, Richard Crowley, Ling Xue, Karl J. Schweighofer, Leo WK. Cheung, Sidney Hsieh, Karl Eckert, BA, Matthias Versele, Betty Y. Chang

Blood (2014) 124 (21): 505.

https://doi.org/10.1182/blood.V124.21.505.505

Published: 2014

Journal Articles

Ibrutinib Inhibits Concomitant TLR and BCR- Driven Proliferation of Chronic Lymphocytic Leukemia Cells and Overrides the Supportive Survival-Promoting Effects of Microenvironmental Signals

Sonal Temburni, MS, Jacqueline C. Barrientos, MD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, Kanti R. Rai, MD, Betty Y. Chang, Nicholas Chiorazzi, MD, Rajendra N Damle, PhD

Blood (2014) 124 (21): 3310.

https://doi.org/10.1182/blood.V124.21.3310.3310

Published: 2014

Journal Articles

Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

Jennifer A. Woyach, Engin Bojnik, Amy S. Ruppert, Matthew R. Stefanovski, Virginia M. Goettl, Kelly A. Smucker, Lisa L. Smith, Jason A. Dubovsky, William H. Towns, Jessica MacMurray, Bonnie K. Harrington, Melanie E. Davis, Stefania Gobessi, Luca Laurenti, Betty Y. Chang, Joseph J. Buggy, Dimitar G. Efremov, John C. Byrd, Amy J. Johnson

Blood (2014) 123 (8): 1207–1213.

https://doi.org/10.1182/blood-2013-07-515361

Published: 2014

Includes: Supplemental data

Journal Articles

A Novel Mutation In Bruton Tyrosine Kinase Confers Acquired Resistance To Ibrutinib (PCI-32765) In CLL

Richard R. Furman, MD, Shuhua Cheng, PhD, Pin Lu, MD, PhD, Menu Setty, Alexandar Perez, Ailin Guo, MD, PhD, Joelle Racchumi, BS, Jiao Ma, PhD, Morton Coleman, MD, Kabaleeswaran Venkataraman, PhD, Guozhou Xu, PhD, Wei Chen, PhD, Hao Wu, PhD, Betty Y. Chang, PhD, Christina Leslie, PhD, Y. Lynn Wang, MD, PhD

Blood (2013) 122 (21): 4914.

https://doi.org/10.1182/blood.V122.21.4914.4914

Published: 2013

Journal Articles

Cytokine and T-Cell Phenotypic Changes Upon In Vivo Ibrutinib Therapy For CLL – Targeting Both CLL Cells and The Tumor-Microenvironment

Carsten U Niemann, MD, PhD, Angelique Biancotto, PhD, Betty Y. Chang, PhD, Joseph J. Buggy, PhD, J. Philip McCoy, Jr., Mohammed Farooqui, DO, Adrian Wiestner, MD, PhD

Blood (2013) 122 (21): 2856.

https://doi.org/10.1182/blood.V122.21.2856.2856

Published: 2013

Journal Articles

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Blood (2013) 122 (15): 2539–2549.

https://doi.org/10.1182/blood-2013-06-507947

Published: 2013

Includes: Supplemental data

Journal Articles

Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Betty Y. Chang, Michelle Francesco, Martin F. M. De Rooij, Padmaja Magadala, Susanne M. Steggerda, Min Mei Huang, Annemieke Kuil, Sarah E. M. Herman, Stella Chang, Steven T. Pals, Wyndham Wilson, Adrian Wiestner, Marcel Spaargaren, Joseph J. Buggy, Laurence Elias

Blood (2013) 122 (14): 2412–2424.

https://doi.org/10.1182/blood-2013-02-482125

Published: 2013

Includes: Supplemental data

Journal Articles

Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease

Jennifer A. Woyach, MD, Matthew R Stefanovski, B.S., Virginia Goettl, Amy S. Ruppert, MAS, Kelly A Smucker, Lisa L. Smith, Jason A Dubovsky, Ph.D, William H. Towns, Jessica MacMurray, Melanie E. Davis, Yicheng Mao, Betty Y. Chang, PhD, Joseph J. Buggy, PhD, John C. Byrd, MD, Amy J Johnson, PhD

Blood (2012) 120 (21): 183.

https://doi.org/10.1182/blood.V120.21.183.183

Published: 2012

Journal Articles

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Blood (2012) 120 (21): 775.

https://doi.org/10.1182/blood.V120.21.775.775

Published: 2012

Journal Articles

Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Ravi Vij, MD, Betty Y. Chang, PhD, Jesus G. Berdeja, MD, Carol Ann Huff, M.D., Nikoletta Lendvai, MD PhD, Yu-Tzu Tai, PhD, Stella Chang, Davina Moussa, Joseph J. Buggy, PhD, Laurence Elias, MD, Paul G. Richardson, MD

Blood (2012) 120 (21): 4039.

https://doi.org/10.1182/blood.V120.21.4039.4039

Published: 2012

Journal Articles

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

Blood (2012) 120 (9): 1877–1887.

https://doi.org/10.1182/blood-2011-12-396853

Published: 2012

Includes: Supplemental data

Journal Articles

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

Martin F. M. de Rooij, Annemieke Kuil, Christian R. Geest, Eric Eldering, Betty Y. Chang, Joseph J. Buggy, Steven T. Pals, Marcel Spaargaren

Blood (2012) 119 (11): 2590–2594.

https://doi.org/10.1182/blood-2011-11-390989

Published: 2012

Includes: Supplemental data

Journal Articles

Targeting Brouton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenström Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, and Myeloma Stem-Like Cells in the Bone Marrow Microenvironment

Blood (2011) 118 (21): 883.

https://doi.org/10.1182/blood.V118.21.883.883

Published: 2011

NARROW

Ibrutinib inhibits pre-BCR + B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK

Ibrutinib Potentiated NK Cell-Mediated Cytotoxicity in Mouse Models of B-Cell Lymphomas

Mutation Impact of Targeted Genes in Diffuse Large B-Cell Lymphoma Patients Treated with Ibrutinib

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP

The Role of PIM1 in the Ibrutinib-Resistant ABC Subtype of Diffuse Large B-Cell Lymphoma

Outcome of Ibrutinib Treatment by Baseline Genetic Features in Patients with Relapsed or Refractory CLL/SLL with del17p in the Resonate-17 Study

In Vivo Evidence That Ibrutininb Deregulates Chemokine Receptor CXCR4 Surface Membrane Expression and Signaling, Along with Inhibiting B Cell Antigen Receptor Signaling, As Causes for Defective Homing and Impaired Retention of CLL Cells in Tissues

Combination of Ibrutinib and BCL-2 or SYK Inhibitors in Ibrutinib Resistant ABC-Subtype of Diffuse Large B-Cell Lymphoma

Ibrutinib Inhibits Concomitant TLR and BCR- Driven Proliferation of Chronic Lymphocytic Leukemia Cells and Overrides the Supportive Survival-Promoting Effects of Microenvironmental Signals

Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

A Novel Mutation In Bruton Tyrosine Kinase Confers Acquired Resistance To Ibrutinib (PCI-32765) In CLL

Cytokine and T-Cell Phenotypic Changes Upon In Vivo Ibrutinib Therapy For CLL – Targeting Both CLL Cells and The Tumor-Microenvironment

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Egress of CD19 + CD5 + cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Early Changes in Cytokines, Chemokines and Indices of Bone Metabolism in a Phase 2 Study of the Bruton Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

Targeting Brouton's Tyrosine Kinase with PCI-32765 Blocks Growth and Survival of Multiple Myeloma and Waldenström Macroglobulinemia Via Potent Inhibition of Osteoclastogenesis, Cytokines/Chemokine Secretion, and Myeloma Stem-Like Cells in the Bone Marrow Microenvironment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only